Brenus Pharma and InSphero Present Promising 3D Tumor Model Results for Colorectal Cancer Therapy

Brenus Pharma and InSphero’s Presentation

Presentation

InSphero, a leader in 3D cell-based assay technologies, of Swiss and Brenus pharma, a French biotech known for its next-generation excellent immunotherapies, showcased data at the European Association for Cancer Research 2025 annual congress. The data confirmed and highlighted the effective use of 3D tumor spheroids for testing of STC-1010, one of the Brenus primary candidates for colorectal cancer.

Tumor Spheroids

With the funding of the EUROSTARS program, the collaboration between these two companies has led to successfully confirmed the vitrified 3D colorectal cancer spheroids with tumor cell lines aligned with fibroblasts. The vitrification method strengthens integrity, viability (after thawing), and preserves morphology. It also serves accurate evaluation of the STC-1010 therapeutic ability under similar in vivo human tumor conditions.

The previous studies highlighted that STC-1010 antigens were processed effectively by monocyte-derived dendritic cells, which activate CD8+ T cells. The T cells reduce apoptosis in 3D and 2D colorectal cancer models and release anti-tumor cytokines granzyme B and IFNγ. These data accelerate the therapeutic potential of STC-1010.

How are Different Schemes and Platforms Encouraging Development in the Healthcare Market?

The technological advancement and various innovations get recognition through governmental schemes and competitive platforms. The 3D tumor spheroids received confirmation at the European annual congress. This brought innovation to the knowledge and received appreciation. By far, Brenus Pharma's innovative development in cancer immunotherapies has significantly contributed to the tumors and cancers. The programs bolster recognition and funding, and exceed the chain of engagement and new development that further contribute to the healthcare sector.

Additionally, Brenus' participation in France 2030’s biotherapy-bioproduction acceleration strategy and the creative destruction lab (CDL) program was an appreciative effort. Whereas, InSphero offers stimulating programs, including award programs with effective collaboration with the PCRM. Several initiatives of InSphero granted a chance to Brenus, and so the company was also attracted to Brenus’s technological innovation.

Views and Statements

CSO of Brenus Pharma, Benoit Pinteur, said, “The collaboration has allowed us to scale the 3D model and represent the best into our SGC platform. It is a valuable step towards the assessable ability and will elevate the development of future candidates and STC-1010.”

CEO of InSphero, Jan Lichtenberg, said, “The company is proud to support Brenus with our brilliant cryopreserved 3D tumor models. This excellent work demonstrates how advancement will fuel the vitro system and fill the gap between clinical reality and immunotherapies.”